April 26, 2023 08:37 PM EDTUpdated April 28, 03:14 PM
FDA+

In vic­to­ry for mi­cro­bio­me com­pa­ny, FDA ap­proves pills pu­ri­fied from poop

Ryan Cross

Senior Science Correspondent

Seres Ther­a­peu­tics has of­fi­cial­ly tak­en the poop out of poop pills. On Wednes­day, the Cam­bridge-based biotech com­pa­ny scored an FDA ap­proval for its first drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times